Statin‐associated muscle symptoms—A review: Individualizing the approach to optimize care

B. Wiggins, J. Backes, D. Hilleman
{"title":"Statin‐associated muscle symptoms—A review: Individualizing the approach to optimize care","authors":"B. Wiggins, J. Backes, D. Hilleman","doi":"10.1002/phar.2681","DOIUrl":null,"url":null,"abstract":"The 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors, also known as “statins” are considered first‐line pharmacologic therapy for reducing low‐density lipoprotein cholesterol (LDL‐C). They have been demonstrated efficacy in a variety of patients populations to reduce atherosclerotic cardiovascular disease (ASCVD) risk. Like any pharmacologic therapy, however, they are not without possible adverse effects that can lead to discontinuation, thus leading to a loss of benefit. The most common side effect related to statin therapy impacting compliance is musculoskeletal related, commonly referred to as statin‐associated muscle systems (SAMS). While the overall incidence is relatively low, the consequences of nonadherence to statin therapy can have a negative impact on patient care. Therefore, it is important for healthcare providers to understand risk factors, how to diagnose, and how to manage this unfortunate adverse effect in order to optimize care.","PeriodicalId":19812,"journal":{"name":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/phar.2681","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

Abstract

The 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors, also known as “statins” are considered first‐line pharmacologic therapy for reducing low‐density lipoprotein cholesterol (LDL‐C). They have been demonstrated efficacy in a variety of patients populations to reduce atherosclerotic cardiovascular disease (ASCVD) risk. Like any pharmacologic therapy, however, they are not without possible adverse effects that can lead to discontinuation, thus leading to a loss of benefit. The most common side effect related to statin therapy impacting compliance is musculoskeletal related, commonly referred to as statin‐associated muscle systems (SAMS). While the overall incidence is relatively low, the consequences of nonadherence to statin therapy can have a negative impact on patient care. Therefore, it is important for healthcare providers to understand risk factors, how to diagnose, and how to manage this unfortunate adverse effect in order to optimize care.
他汀类药物相关肌肉症状:个体化方法优化护理综述
3 -羟基- 3 -甲基戊二酰辅酶A还原酶抑制剂,也被称为“他汀类药物”,被认为是降低低密度脂蛋白胆固醇(LDL - C)的一线药物治疗。它们在各种患者群体中已被证明具有降低动脉粥样硬化性心血管疾病(ASCVD)风险的功效。然而,像任何药物治疗一样,它们并非没有可能导致停药的副作用,从而导致益处的丧失。他汀类药物治疗影响依从性的最常见副作用是与肌肉骨骼相关的,通常被称为他汀类药物相关肌肉系统(SAMS)。虽然总体发病率相对较低,但不坚持他汀类药物治疗的后果可能对患者护理产生负面影响。因此,对于医疗保健提供者来说,了解风险因素、如何诊断以及如何管理这种不幸的不利影响以优化护理是很重要的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信